NUDCD1 anticorps (AA 431-530) (Biotin)

N° du produit ABIN6944331

Cet anticorps Lapin Polyclonal détecte spécifiquement NUDCD1 dans WB, ELISA, IHC (p) et IHC (fro). Il présente une réactivité envers Souris.

Aperçu rapide pour NUDCD1 anticorps (AA 431-530) (Biotin) (ABIN6944331)

Antigène: NUDCD1 (NudC Domain Containing 1 (NUDCD1))

Reactivité: Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp NUDCD1 est conjugé à/à la Biotin

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Détail du produit anti-NUDCD1 anticorps (Biotin)

Épitope: AA 431-530

Réactivité croisée: Souris

Homologie: Human,Rat,Dog,Cow,Sheep,Horse,Rabbit,Zebrafish

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human NUDCD1

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C for 12 months.

Date de péremption: 12 months

Détails sur NUDCD1

Antigène: NUDCD1 (NudC Domain Containing 1 (NUDCD1))

Autre désignation: NUDCD1

Sujet:

Synonyms: 4921532K09Rik, AA407246, AW260430, AW556235, Chronic myelogenous leukemia tumor antigen 66, CML66, CML66 L, FLJ14991, NudC domain containing 1, NudC domain-containing protein 1, NUDC1_HUMAN, nudcd1, OVA66, RGD1310624, Tumor antigen CML66.

Background: The NUDCD1 gene encodes the 583 amino acid CML66 protein which demonstrates expression in a variety of solid tumor cell lines and leukemias. Expression of CML66 in normal tissues is restricted to testis and heart. The CML66 antibody is found in sera of 18-38 % of patients with lung cancer, melanoma or prostate cancer. These findings indicate that CML66 may be immunogenic in a wide variety of malignancies and may be a target for antigen-specific immunotherapy. A short isoform of CML66, designated CML66-S, is a product of alternative splicing. CML66-S has the same C-terminus as full-lenghth CML66 (also designated CML66-L), but has a unique N-terminus. CML66-S shows predominant expression in testis, and is also expressed in very low levels in tumor cells, while CML66 is expressed in tumor cells and testis.

ID gène: 84955

UniProt: Q96RS6